Eli Lilly seals $1bn genetics deal


Rory O'Neill

Eli Lilly seals $1bn genetics deal

Jonathan Weiss / Shutterstock.com

Eli Lilly is expanding its genetics business with the $880 million purchase of Prevail Therapeutics, in a deal that could rise to more than $1 billion.

Eli, Lilly, Prevail, Therapeutics, genetics, Gaucher, disease, Mark, Mintun, Parkinson, neurodegenerative, dementia, pipeline